GlassScriptPhysician profile
Carlos Rivera
NPI 1518365063
$11,522.75
in general payments reported to CMS, 2019-2025
41 companies · $2,397 in 2025
The $2,397 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $578 · 2021: $1,235 · 2022: $1,295 · 2023: $2,137 · 2024: $2,819 · 2025: $2,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,159 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,158.63 |
| Education | $195.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,415.76 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| Janssen Pharmaceuticals, INC | $1,094.91 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Amgen INC. | $1,014.67 | 2019-2025 | Xgeva, Lumakras, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $805.29 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $782.02 | 2020-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eli Lilly Export S.A. Puerto Rico Branch | $768.02 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $613.41 | 2019-2025 | Venclexta, Epkinly |
| Pbg Puerto Rico LLC | $562.01 | 2019-2025 | |
| Genzyme Corporation | $507.45 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $475.71 | 2020-2025 | Ninlaro |
| Novartis Pharmaceuticals Corporation | $415.30 | 2021-2025 | |
| Pfizer INC. | $333.68 | 2019-2024 | |
| Genentech USA, INC. | $261.13 | 2021-2025 | Tecentriq, Polivy, Columvi |
| Eisai INC. | $223.16 | 2020-2024 | |
| Incyte Corporation | $183.22 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $178.67 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Sobi, INC | $176.97 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $172.97 | 2023-2025 | Tlando, Trelstar |
| Janssen Biotech, INC. | $154.94 | 2019-2025 | Erleada |
| Exelixis INC. | $150.37 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $144.76 | 2019-2021 | |
| Karyopharm Therapeutics INC. | $124.90 | 2022 | |
| Bard Peripheral Vascular, INC. | $119.33 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $114.24 | 2024-2025 | Libtayo |
| Beigene USA, INC. | $106.76 | 2021-2024 | Brukinsa |
| Bayer Puerto Rico INC. | $91.50 | 2023-2025 | Nubeqa, Stivarga |
| Pharmaessentia USA Corporation | $74.04 | 2025 | Besremi |
| Glaxosmithkline, LLC. | $65.08 | 2023-2024 | Zejula, Jemperli, Ojjaara |
| Tempus Ai, INC | $63.56 | 2025 | Xt Cdx |
| Caris Mpi, INC. | $52.57 | 2025 | Mi Cancer Seek |
| Sanofi-Aventis U.S. LLC | $43.48 | 2020-2021 | |
| Gilead Sciences, INC. | $43.17 | 2024-2025 | Trodelvy |
| Organon LLC | $25.00 | 2025 | |
| Beone Medicines USA, INC. | $24.53 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $24.02 | 2022 | |
| Global Blood Therapeutics, INC. | $24.00 | 2022 | |
| Stemline Therapeutics INC. | $23.45 | 2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $18.94 | 2019 | |
| Seagen INC. | $16.96 | 2019 | |
| Immunogen, INC. | $16.54 | 2024 | Elahere |
| Alexion Pharmaceuticals, INC. | $16.26 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.